Lilly to Acquire Merida for Up to $2.88 Billion in Autoimmune Disease Push

Eli Lilly & Co. plans to acquire Merida Biosciences Inc. for up to $2.88 billion in cash, aiming to expand its footprint in autoimmune and allergic diseases. This move is part of the company's strategy to diversify beyond its blockbuster weight-loss and diabetes drugs. Lilly is investing in new therapeutic areas to solidify its position as the world's largest pharmaceutical company. The company has been on a record acquisition spree in 2026, with deals exceeding $20 billion so far. This spending surge is fueled by cash flows from its Zepbound and Mounjaro injections, which are being redirected, particularly toward early-stage drug candidates. Through these efforts, Lilly aims to diversify its portfolio to develop future blockbuster therapies. The acquisition of Merida will strengthen Lilly's presence in autoimmune diseases and add new treatment options to its R&D pipeline. The deal is seen as a significant step in Lilly's long-term growth strategy. Bloomberg News Senior Global Business Editor Michelle Cortez commented on this development. This is not investment advice.